The article, titled: "The impact of lures on a mobile digitized n-back," outlines a new digitized version of the n-back test, a routinely used instrument in neurocognitive research, as a cognitive tool to evaluate for the effects of lures in a 2-back task.
The research study had 1314 participants, ranging from 15 to 76 years of age, who agreed to participate and were part of a larger validation study.
This study evaluated whether there was an added cognitive cost that a lure would elicit and assumed it would adversely affect performance.
The results indicated that the occurrence of a lure seemed to have a facilitatory effect in terms of faster response time to targets when a lure was present.
Because a 2-back task can be cognitively challenging, the researchers also had expected that over the course of the 60-trial test that subjects would exhibit cognitive fatigue as manifested by slower response time and decreased accuracy.
Instead, the study found that subjects' performance improved in both response time and accuracy over the course of the test whether lures were present or not.
Additionally, the study postulated that the modality and paradigm used in n-back studies may be considered as significant factors when comparing different studies.
Savonix offers a mobile assessment of cognitive function available on Android and iOS for phone and tablet, the Savonix Cognitive Assessment platform is an accurate, accessible and affordable tool for professional cognitive screens.
It empowers healthcare providers, payers and researchers to evaluate and leverage results to improve health and treatment outcomes. Led by clinical neuropsychologists and digital health technology experts, the company has established itself as an authority on cognition globally.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA